X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-18 | SEPN | Septerna, Inc. | Bhatt Elizabeth | Pres, COO | S - Sale+OE | $28.97 | -4,000 | 174,209 | -2% | -$115,860 | |||||
2026-02-18 | PTCT | Ptc Therapeutics, Inc. | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | S - Sale | $69.36 | -2,494 | 70,199 | -3% | -$172,984 | ||||||
2026-02-18 | PTCT | Ptc Therapeutics, Inc. | Gravier Pierre | CFO | S - Sale | $69.36 | -2,992 | 87,318 | -3% | -$207,525 | ||||||
2026-02-18 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CHIEF BUSINESS OFFICER | S - Sale | $69.36 | -3,019 | 77,122 | -4% | -$209,398 | ||||||
2026-02-18 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $69.36 | -7,371 | 387,082 | -2% | -$511,253 | ||||||
2026-02-18 | PTCT | Ptc Therapeutics, Inc. | Golden Lee Scott | EVP, CHIEF MEDICAL OFFICER | S - Sale | $69.36 | -2,484 | 89,944 | -3% | -$172,290 | ||||||
2026-02-18 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale | $69.36 | -3,121 | 118,866 | -3% | -$216,473 | ||||||
2026-02-18 | PLYX | Polaryx Therapeutics, Inc. | Landis G. Michael | CFO | P - Purchase | $2.79 | +2,867 | 228,225 | +1% | +$7,991 | ||||||
2026-02-18 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $3.34 | -1,157 | 91,019 | -1% | -$3,862 | ||||||
2026-02-18 | ANNX | Annexon, Inc. | Dananberg Jamie | Chief Medical Officer | S - Sale | $5.10 | -5,290 | 73,152 | -7% | -$26,979 | ||||||
2026-02-18 | ANNX | Annexon, Inc. | Lew Jennifer | EVP, CFO | S - Sale | $5.11 | -7,851 | 113,765 | -6% | -$40,119 | ||||||
2026-02-18 | ANNX | Annexon, Inc. | Artis Dean Richard | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $5.10 | -5,290 | 123,487 | -4% | -$26,979 | ||||||
2026-02-18 | ANNX | Annexon, Inc. | Yednock Ted | EVP, CHIEF INNOVATION OFFICER | S - Sale | $5.11 | -7,857 | 97,227 | -7% | -$40,149 | ||||||
2026-02-18 | ANNX | Annexon, Inc. | Overdorf Michael | EVP, CHIEF BUSINESS OFFICER | S - Sale | $5.10 | -6,225 | 124,464 | -5% | -$31,748 | ||||||
2026-02-18 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $3.34 | -5,990 | 1,452,293 | 0% | -$19,995 | ||||||
2026-02-19 | KROS | Keros Therapeutics, Inc. | Seehra Jasbir | CEO | S - Sale | $16.17 | -7,015 | 385,708 | -2% | -$113,433 | ||||||
2026-02-18 | KROS | Keros Therapeutics, Inc. | Lerner Lorena Raquel | Chief Science Officer | S - Sale | $16.35 | -3,873 | 31,127 | -11% | -$63,324 | ||||||
2026-02-18 | KROS | Keros Therapeutics, Inc. | Cho Esther | SVP, GC | S - Sale | $16.35 | -4,745 | 39,755 | -11% | -$77,581 | ||||||
2026-02-18 | KROS | Keros Therapeutics, Inc. | Regnante Keith | CFO | S - Sale | $16.35 | -4,739 | 39,261 | -11% | -$77,483 | ||||||
2026-02-18 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $3.34 | -1,376 | 682,000 | 0% | -$4,593 | ||||||
| D | 2026-02-19 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale+OE | $16.00 | -100 | 162,894 | 0% | -$1,600 | |||||
| D | 2026-02-18 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $79.40 | -4,302 | 0 | -100% | -$341,564 | |||||
2026-02-18 | ALXO | Alx Oncology Holdings Inc | Pinto Shelly | SVP, Finance, CAO | S - Sale | $2.27 | -565 | 87,708 | -1% | -$1,283 | ||||||
| M | 2026-02-17 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale | $101.31 | -7,954 | 110,512 | -7% | -$805,814 | |||||
| D | 2026-02-18 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $15.00 | -1,038 | 429,667 | 0% | -$15,570 | |||||
| D | 2026-02-18 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | CHIEF MEDICAL OFFICER | S - Sale+OE | $15.00 | -1,163 | 133,087 | -1% | -$17,445 | |||||
| D | 2026-02-18 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $15.00 | -1,109 | 224,173 | 0% | -$16,635 | |||||
2026-02-18 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $29.35 | -10,916 | 658,705 | -2% | -$320,373 | ||||||
| D | 2026-02-17 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale+OE | $29.02 | -8,500 | 393,075 | -2% | -$246,655 | |||||
2026-02-17 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $26.18 | -1,230 | 171,865 | -1% | -$32,196 | ||||||
| D | 2026-02-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief Medical Officer | S - Sale+OE | $26.17 | -45,000 | 25,000 | -64% | -$1,177,862 | |||||
| D | 2026-02-18 | GERN | Geron Corp | Robertson Michelle | EVP, CFO | S - Sale+OE | $1.94 | -9,855 | 17,645 | -36% | -$19,119 | |||||
| M | 2026-02-17 | IRON | Disc Medicine, Inc. | Franchi Jean M. | CFO | S - Sale | $64.51 | -11,156 | 71,343 | -14% | -$719,727 | |||||
| DM | 2026-02-17 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $69.33 | -5,894 | 108,231 | -5% | -$408,613 | |||||
| D | 2026-02-19 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $476.34 | -8,300 | 36,781 | -18% | -$3,953,588 | |||||
| M | 2026-02-17 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $483.52 | -977 | 48,650 | -2% | -$472,395 | |||||
| M | 2026-02-17 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bunnage Mark E. | EVP, Chief Scientific Officer | S - Sale | $484.31 | -3,619 | 8,486 | -30% | -$1,752,704 | |||||
| D | 2026-02-17 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | GC, GC | S - Sale+OE | $27.83 | -10,000 | 105,211 | -9% | -$278,315 | |||||
| M | 2026-02-17 | VRTX | Vertex Pharmaceuticals Inc / Ma | Biller Jonathan | EVP, GC | S - Sale | $484.18 | -3,720 | 15,748 | -19% | -$1,801,161 | |||||
| M | 2026-02-17 | VRTX | Vertex Pharmaceuticals Inc / Ma | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Offi | S - Sale | $484.93 | -2,848 | 20,727 | -12% | -$1,381,090 | |||||
| M | 2026-02-17 | VRTX | Vertex Pharmaceuticals Inc / Ma | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $484.87 | -2,195 | 7,750 | -22% | -$1,064,297 | |||||
2026-02-17 | KPTI | Karyopharm Therapeutics Inc. | Poulton Stuart | EVP, Chief Development Officer | S - Sale | $8.63 | -378 | 99,429 | 0% | -$3,262 | ||||||
| DM | 2026-02-13 | JNJ | Johnson & Johnson | Swanson James D. | EVP, CIO | S - Sale+OE | $243.39 | -62,080 | 25,698 | -71% | -$15,109,759 | |||||
| D | 2026-02-17 | JNJ | Johnson & Johnson | Wolk Joseph J | EVP, CFO | S - Sale+OE | $242.80 | -89,654 | 85,008 | -51% | -$21,767,827 | |||||
| D | 2026-02-17 | JNJ | Johnson & Johnson | Reed John C | EVP, Innovative Medicine, R, D | S - Sale+OE | $243.00 | -53,931 | 10,658 | -83% | -$13,105,233 | |||||
| D | 2026-02-18 | JNJ | Johnson & Johnson | Schmid Timothy | EVP, WW Chair, MedTech | S - Sale+OE | $244.33 | -22,623 | 27,560 | -45% | -$5,527,506 | |||||
| D | 2026-02-17 | JNJ | Johnson & Johnson | Broadhurst Vanessa | EVP, Global Corp Affairs | S - Sale+OE | $243.39 | -6,197 | 23,003 | -21% | -$1,508,288 | |||||
| M | 2026-02-13 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $51.68 | -14,080 | 53,520 | -21% | -$727,646 | |||||
2026-02-13 | MPLT | Maplight Therapeutics, Inc. | Malenka Robert C. | Dir | S - Sale | $18.21 | -12,116 | 370,926 | -3% | -$220,632 | ||||||
| D | 2026-02-17 | TERN | Terns Pharmaceuticals, Inc. | Burroughs Amy L. | CEO | S - Sale+OE | $39.19 | -14,583 | 297,295 | -5% | -$571,579 | |||||
2026-02-17 | BBIO | Bridgebio Pharma, Inc. | Apuli Maricel | Chief Accounting Officer | S - Sale | $74.31 | -510 | 123,945 | 0% | -$37,898 | ||||||
2026-02-17 | BBIO | Bridgebio Pharma, Inc. | Trimarchi Thomas | Pres, CFO | S - Sale | $74.72 | -13,600 | 336,585 | -4% | -$1,016,147 | ||||||
| D | 2026-02-17 | BBIO | Bridgebio Pharma, Inc. | Scott Randal W. | Dir | S - Sale+OE | $75.46 | -10,000 | 15,589 | -39% | -$754,557 | |||||
2026-02-13 | ARVN | Arvinas, Inc. | Teel Randy | Pres, CEO | S - Sale | $11.89 | -4,403 | 154,482 | -3% | -$52,352 | ||||||
2026-02-13 | ARVN | Arvinas, Inc. | Saik Andrew | CFO | S - Sale | $11.89 | -5,134 | 159,267 | -3% | -$61,043 | ||||||
2026-02-13 | ARVN | Arvinas, Inc. | Cacace Angela M | Chief Scientific Officer | S - Sale | $11.89 | -4,592 | 151,232 | -3% | -$54,599 | ||||||
| D | 2026-02-17 | PTGX | Protagonist Therapeutics, Inc | Williams Lewis T | Dir | S - Sale+OE | $82.42 | -18,000 | 7,825 | -70% | -$1,483,560 | |||||
2026-02-13 | ARVN | Arvinas, Inc. | Berkowitz Noah | Chief Medical Officer | S - Sale | $11.89 | -5,685 | 163,938 | -3% | -$67,595 | ||||||
2026-02-13 | ARVN | Arvinas, Inc. | Loomis David K | Chief Accounting Officer | S - Sale | $11.89 | -1,016 | 30,800 | -3% | -$12,080 | ||||||
| D | 2026-02-13 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $26.49 | -200,000 | 1,654,597 | -11% | -$5,298,000 | |||||
2026-02-13 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $3.31 | -12,253 | 683,376 | -2% | -$40,582 | ||||||
2026-02-13 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $3.31 | -3,726 | 92,176 | -4% | -$12,341 | ||||||
2026-02-13 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $3.31 | -12,279 | 1,458,283 | -1% | -$40,668 | ||||||
| D | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | Merendino Lauren | Chief Commercial Officer | S - Sale+OE | $11.60 | -5,814 | 60,157 | -9% | -$67,448 | |||||
2026-02-13 | AVDL | Avadel Pharmaceuticals Plc | Weiss Asset Management LP | Former 10% Owner | S - Sale | $21.00 | -11,112,052 | 0 | -100% | -$233,353,092 | ||||||
| D | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | Dubow Adam | GC, Secretary | S - Sale+OE | $11.60 | -6,395 | 72,694 | -8% | -$74,188 | |||||
| D | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | COO, CFO | S - Sale+OE | $11.60 | -6,065 | 312,025 | -2% | -$70,359 | |||||
| D | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | Bender Jeremy | CEO | S - Sale+OE | $11.60 | -15,459 | 1,798,991 | -1% | -$179,338 | |||||
| D | 2026-02-17 | DAWN | Day One Biopharmaceuticals, Inc. | Vasconcelles Michael | Head of Research, Dev. | S - Sale+OE | $11.60 | -2,728 | 4,397 | -38% | -$31,647 | |||||
2026-02-13 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $499.99 | -1,500 | 46,132 | -3% | -$749,985 | ||||||
2026-02-17 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Hodgson Ian | COO | S - Sale | $7.38 | -847 | 51,080 | -2% | -$6,253 | ||||||
2026-02-13 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Moran Sean F. | CFO | S - Sale | $7.78 | -4,701 | 96,694 | -5% | -$36,588 | ||||||
| D | 2026-02-17 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $480.75 | -22,500 | 2,648 | -89% | -$10,816,956 | |||||
| M | 2026-02-13 | LXRX | Lexicon Pharmaceuticals, Inc. | Debbane Raymond | Dir | P - Purchase | $1.31 | +268,497 | 51,408,909 | +1% | +$352,889 | |||||
| D | 2026-02-15 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Dir | S - Sale+OE | $8.47 | -259 | 11,577 | -2% | -$2,194 | |||||
2026-02-13 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | CEO | S - Sale | $7.78 | -13,871 | 174,316 | -7% | -$107,952 | ||||||
| D | 2026-02-15 | MCRB | Seres Therapeutics, Inc. | Young Teresa L. | See Remarks | S - Sale+OE | $8.47 | -75 | 8,557 | -1% | -$635 | |||||
| D | 2026-02-15 | MCRB | Seres Therapeutics, Inc. | Desrosier Thomas | See Remarks | S - Sale+OE | $8.47 | -78 | 7,789 | -1% | -$661 | |||||
| D | 2026-02-15 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | See Remarks | S - Sale+OE | $8.47 | -89 | 7,677 | -1% | -$754 | |||||
2026-02-13 | VRTX | Vertex Pharmaceuticals Inc / Ma | Biller Jonathan | EVP, GC | S - Sale | $499.00 | -988 | 16,838 | -6% | -$493,012 | ||||||
2026-02-13 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bhatia Sangeeta N. | Dir | S - Sale | $500.00 | -266 | 4,299 | -6% | -$133,000 | ||||||
2026-02-13 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $63.00 | +291 | 460,335 | 0% | +$18,333 | ||||||
| D | 2026-02-15 | TEVA | Teva Pharmaceutical Industries Ltd | Francis Richard D | Pres, CEO | S - Sale+OE | $34.22 | -447,778 | 605,771 | -43% | -$15,324,799 | |||||
| A | 2026-02-02 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $58.00 | +100 | 460,044 | 0% | +$5,800 | |||||
2026-02-17 | IRON | Disc Medicine, Inc. | Khara Rahul | GC | S - Sale | $62.86 | -2,853 | 52,173 | -5% | -$179,340 | ||||||
2026-02-17 | IRON | Disc Medicine, Inc. | Stephenson Pamela | Chief Commercial Officer | S - Sale | $62.86 | -5,531 | 80,998 | -6% | -$347,679 | ||||||
| D | 2026-02-10 | ERNA | Ernexa Therapeutics Inc. | Cherington Charles | 10% | P - Purchase | $0.50 | +4,000,000 | 6,779,440 | +144% | +$2,000,000 | |||||
2026-02-17 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale | $62.86 | -3,256 | 92,589 | -3% | -$204,672 | ||||||
2026-02-17 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale | $62.86 | -3,231 | 54,324 | -6% | -$203,101 | ||||||
2026-02-17 | IRON | Disc Medicine, Inc. | Quisel John D | CEO | S - Sale | $62.86 | -13,264 | 226,064 | -6% | -$833,775 | ||||||
2026-02-12 | OCUL | Ocular Therapeutix, Inc | Notman Donald | COO | S - Sale | $9.04 | -11,446 | 366,356 | -3% | -$103,472 | ||||||
2026-02-12 | OCUL | Ocular Therapeutix, Inc | Nayak Sanjay | Chief Strategy Officer | S - Sale | $9.04 | -10,348 | 332,412 | -3% | -$93,546 | ||||||
2026-02-12 | OCUL | Ocular Therapeutix, Inc | Dugel Pravin | See Remarks | S - Sale | $9.04 | -124,882 | 3,333,193 | -4% | -$1,128,933 | ||||||
2026-02-12 | OCUL | Ocular Therapeutix, Inc | Waheed Nadia | Chief Medical Officer | S - Sale | $9.04 | -7,863 | 318,417 | -2% | -$71,082 | ||||||
2026-02-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Garg Pushkal | EVP Chief R, D | S - Sale | $310.08 | -2,242 | 25,529 | -8% | -$695,201 | ||||||
2026-02-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Greenstreet Yvonne | CEO | S - Sale | $310.08 | -6,958 | 86,069 | -7% | -$2,157,542 | ||||||
2026-02-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Tanguler Tolga | EVP, Chief Commercial Officer | S - Sale | $310.08 | -1,959 | 31,769 | -6% | -$607,448 | ||||||
| M | 2026-02-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $321.25 | -4,000 | 21,801 | -16% | -$1,284,980 | |||||
2026-02-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $310.08 | -2,242 | 59,859 | -4% | -$695,201 | ||||||
| D | 2026-02-17 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $27.59 | -417 | 44,089 | -1% | -$11,505 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |